Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Auer

Showing results (41-50 of 120) with videos related to

Pageof 12
Sort By:
European Journal of Neurology|September 6, 2025
Kappa Free Light Chain Index in the Real World-Do We Miss Clinically Relevant Information by Skipping Oligoclonal Banding?Harald Hegen, Martin Schmidauer, Michael Auer, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|December 6, 2016
Serum Cotinine Does Not Predict Neutralizing Antibodies Against Interferon Beta in an Austrian MS CohortMichael Auer, Harald Hegen, Thomas Luft, et al.
Multiple Sclerosis and Related Disorders|November 26, 2022
Chasing shadows: Cytologically detected shadow cells in the cerebrospinal fluid of patients with multiple sclerosisKlaus Berek, Franziska Di Pauli, Michael Auer, et al.
Brain and Behavior|June 7, 2019
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective studyMichael Auer, Harald Hegen, Johann Sellner, et al.
European Journal of Neurology|August 7, 2025
Kappa Free Light Chain Index and Oligoclonal Bands in Varicella Zoster Virus Infection and Neuroborreliosis: A Matter of Timing?Klaus Berek, Martin Schmidauer, Michael Auer, et al.
Frontiers in Immunology|July 5, 2021
Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric StudyKlaus Berek, Gabriel Bsteh, Michael Auer, et al.
Multiple Sclerosis and Related Disorders|May 30, 2020
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximabMichael Auer, Gabriel Bsteh, Harald Hegen, et al.
Plos One|March 21, 2017
Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal studyHarald Hegen, Michael Auer, Gabriel Bsteh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 4, 2018
Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western AustriaGabriel Bsteh, Laura Algrang, Harald Hegen, et al.
European Journal of Neurology|September 26, 2020
Multiple sclerosis and COVID-19: How many are at risk?Gabriel Bsteh, Christina Bitschnau, Harald Hegen, et al.
Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
European Journal of Neurology|September 6, 2025
Kappa Free Light Chain Index in the Real World-Do We Miss Clinically Relevant Information by Skipping Oligoclonal Banding?Harald Hegen, Martin Schmidauer, Michael Auer, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|December 6, 2016
Serum Cotinine Does Not Predict Neutralizing Antibodies Against Interferon Beta in an Austrian MS CohortMichael Auer, Harald Hegen, Thomas Luft, et al.
Multiple Sclerosis and Related Disorders|November 26, 2022
Chasing shadows: Cytologically detected shadow cells in the cerebrospinal fluid of patients with multiple sclerosisKlaus Berek, Franziska Di Pauli, Michael Auer, et al.
Brain and Behavior|June 7, 2019
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective studyMichael Auer, Harald Hegen, Johann Sellner, et al.
European Journal of Neurology|August 7, 2025
Kappa Free Light Chain Index and Oligoclonal Bands in Varicella Zoster Virus Infection and Neuroborreliosis: A Matter of Timing?Klaus Berek, Martin Schmidauer, Michael Auer, et al.
Frontiers in Immunology|July 5, 2021
Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric StudyKlaus Berek, Gabriel Bsteh, Michael Auer, et al.
Multiple Sclerosis and Related Disorders|May 30, 2020
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximabMichael Auer, Gabriel Bsteh, Harald Hegen, et al.
Plos One|March 21, 2017
Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal studyHarald Hegen, Michael Auer, Gabriel Bsteh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 4, 2018
Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western AustriaGabriel Bsteh, Laura Algrang, Harald Hegen, et al.
European Journal of Neurology|September 26, 2020
Multiple sclerosis and COVID-19: How many are at risk?Gabriel Bsteh, Christina Bitschnau, Harald Hegen, et al.
Pageof 12